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Abstract
HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, and is
an attractive target for new anti-HIV drugs. Integrase is an enzyme produced by a retrovirus (such as
HIV) that enables its genetic material to be integrated into the DNA of the infected cell. Raltegravir and
Elvitegravir are two important drugs against integrase.
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1. Introduction
The human immunodeficiency virus type 1 (HIV-1) is the primary cause of the acquired
immunodeficiency syndrome (AIDS), which is a slow, progressive and degenerative disease of
the human immune system. HIV-1 is a lentivirus belonging to the retrovirus family. The virus
is diploid and contains two plus-stranded RNA copies of its genome. The development of
possible methods that can delay progression of the infection or block replication of HIV-1 in
infected individuals has been the subject of dedicated research efforts over the past decades.
One important issue is that HIV-1 makes use of the replication machinery of the host cell,
which minimizes the number of potential viral targets. On the other hand, the close host-virus
relationship limits the evolutionary freedom for the viral components that interact with the host
molecules[1]. Integration of viral DNA into the host chromosome is a necessary process in the
HIV replication cycle [2]. The key steps of DNA integration are carried out by the viral
integrase protein, which, along with protease and reverse transcriptase, is one of three enzymes
encoded by HIV. Combination antiviral therapy with protease and reverse transcriptase
inhibitors has demonstrated the potential therapeutic efficacy of antiviral therapy for treatment
for AIDS [3] . Since HIV integrase has no direct cellular counterpart it presents itself as an
attractive target for therapeutic intervention [4]. Unlike the retroviral reverse transcriptase and
protease enzymes, successful drug candidates based on the inhibition of integrase have yet to
emerge despite the multitude of laboratories working on the problem [5]. The objective of this
study is to discover new analogs with improved potency, physiochemical/metabolic properties
and toxic effects, which can stand as potential inhibitors of AIDS.
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2. Materials and Methods
For the present study bioinformatics tools, biological databases like PubMed, Drug Bank, PDB
(Protein Data Bank) and software’s like Molegro Virtual Docker, ACD ChemSketch, Pharma
Algorithms were used.
The structure of HIV-1 integrase catalytic domain was retrieved from Protein data bank (PDB)
(PDB id: 1BL3) (http://www.pdb.org). It is a 160 residues long protein and contains three
domains, an N-terminal HH-CC zinc finger domain believed to be partially responsible for
multimerization, a central catalytic domain and a C-terminal domain. Both the Central catalytic
domain and C-terminal domains have been shown to bind both viral and cellular DNA.
Currently no crystal structure data exists with Integrase bound to its DNA substrates.
Biochemical data and structural data suggest that integrase functions as a dimer or a tetramer
[6].
Figure 1.  The structure of HIV-1 integrase catalytic domain
The structures of the drugs Raltegravir and Elvitegravir were obtained from Drug Bank
(www.drugbank.ca) and KEGG Drug (www.genome.jp/kegg/drug) respectively. Using
ACDLABS/ChemSketch (www.acdlabs.com) the 2D structures of the analogues of these drugs
were sketched. The analogs were screened for their physiochemical properties at FAF drugs.
The analogs that do not follow Lipinski’s rules are discarded. The selected analogs are then
screened for their bioactivity and toxicity under PASS software. The selected analogs were then
searched against various chemical structure databases for similarity with a existing structure.
The databases taken in this step are: PubChem (pubchem.ncbi.nlm.nih.gov), KEGG, Molsoft
(MolCart) (www.molsoft.com/molcart.html), Hic-Up (xray.bmc.uu.se/hicup/), and ChemBank
(chembank.broadinstitute.org/). No similarity has been detected. The analogs are then
subjected to molecular dynamics analysis in ChemBio3D Ultra under optimum conditions. The
screened analogs were then subjected to Pharma Algorithm predict various pharmacological
effects like oral bioavailability, protein binding etc. The Molecular Docking is performed in
Molegro Virtual Docker (MVD) (http://www.molegro.com/). Possible active sites and cavities
were detected for Chain A of 1BL3 using Molegro Virtual Docker. The following Parameters
were used for Cavity Detection:
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Figure 2. Parameters of Molegro Virtual Docker.
3. Result
3.1 Result of Active Site Prediction and Cavity Detection
The structure of HIV-1 integrase catalytic domain (PDB id: 1BL3) is 160 residues long and
contains three chains: A, B and C. Catalytic core domain is present between 50 – 212 residues
[7] . The position of the active site are Thr (T) =66. Asp (D) =64,116. Val (V) =77. Glu (E) =15
Lys (K) =159 [8, 9]. Active sites and cavities were detected for Chain A of 1BL3 using
Molegro Virtual Docker.
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Figure 3. Positions of active site shown in Molegro Virtual Docker
3.2 Result of Molecular Docking:
The Molecular Docking is performed in Molegro Virtual Docker (MVD) .The following
Parameters were used for Docking using Molegro Virtual Docker. Docker uses the MolDock
docking engine to predict ligand - protein interactions. MolDock is based on a new hybrid
search algorithm, called guided differential evolution [10].
Figure 4. Docking Parameters shown in Molegro Virtual Docker
The imported ligands were manually checked before docking and corrected in those cases were
it had failed. Water molecules with the protein structures were excluded from the docking
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experiments, The docking is then allowed to run for some time for Raltegravir and Elvitegravir
analogs (remained after virtual screening) respectively with the target protein. The poses having
the good MolDock and Docking score are selected for the further analysis.
Figure 4. The result of Docking shown with contacts.
Docking results tabulated between HIV integrase and the conventional drug Raltegravir (Table
1) and Elvitegravir (Table 2) analogs are shown below.
Table 1. Raltegravir analogs Table 2. Elvitegravir analogs
The interactions between the residues of the target protein and analogs showing good docking
score which are derived from the two lead molecules are given below-
Mol_id MolDock
Score
Docking score
RL 40 -150.584 -160.781
RL 13 -144.854 -144.94
RL 4 -143.524 -154.891
RL 3 -142.581 -148.704
Mol_id MolDock
Score
Docking
score
EL 9 -114.166 -199.066
EL 15 -113.443 -118.713
EL 10 -112.471 -112.235
EL 7 -111.277 113.903
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Table 3. Interaction of Raltegravir analogs
Mol_id Residue InteractionDistance (in
Armstrong)
Mol_id Residue Interaction Distance (in
Armstrong)
RL 9
Glu (152) H - H 1.57
RL 28
Glu (152) H - H 1.82
Glu (152) H – H 1.36 Glu (152) H - H 2.01
Gly (140) H – O 2.22 Glu (152) H - H 1.91
Asp(116) H - O 2.28 Asp(64) H - H 2.32
RL 10
Asp(116) O – H 2.19
RL 40
His(114) H - H 1.71
Asp(64) H – H 0.90 Gln(62) N - H 1.80
Gly(140) H – O 2.00 Asp(64) H - H 1.92
Gly(140) H – H 1.66 His(114) H - H 1.78
Table 4. Interaction of Elvitegravir analogs
Mol_id Residue Interaction Distance (in
Armstrong)
Mol_id Residue Interaction Distance (in
Armstrong)
EL 7
Glu (152) H - H 2.09
EL 10
His(114) H - Cl 2.38
Glu (152) H - H 2.36 Glu (152) H - H 2.25
EL 9
Glu (152) H - H 2.02
EL 15
His(114) H - H 1.57
Thr (115) H - H 2.08 Asp(116) H - H 1.87
Asp(64) H - O 2.32 Asp(64) H - H 2.36
Asp(64) H - O 2.37 His(114) H - O 2.15
3.4 Result of Pharma algorithm
Pharma algorithm is a tool for in silico physicochemical, ADME, Metabolism, and Toxicology
screening and prediction. The results for Raltegravir (Table 5) and Elvitegravir (Table 6)
analogs are shown below
Table 5. Pharma algorithm results for Raltegravir
ADME BOX Raltegravir RL 40 RL 28 RL 10 RL 9
Oral bioavailability
between 30% and 70%:
%F(Oral) > 30%: 0.721 0.827 0.721 0.099 0.391
%F(Oral) >70%: 0.351 0.282 0.282 0.080 0.091
Absorption
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Maximum passive
absorption
Contribution from:
Trancellular route 100% 100% 100% 100% 100%
Paracellular route 0% 0% 0% 0% 0%
Permeability:
Human Jejunum scale
(pH=6.5) Pe, Jejunum
=
2.37x10-4
cm/s
2.62x10-4
cm/s
3.60x10-4
cm/s
2.35x10-4
cm/s
1.71x10-4
cm/s
Caco-2 scale (pH=7.4,
500 rpm):
Pe, Caco-2
61.04x10-6
cm/s
121.86x1
0-6 cm/s 159.45x10-
6 cm/s
59.88x10-6
cm/s
27.88x10-6
cm/s
Absorption rate Ka =: 0.080 min-
1
0.085
min-1
0.095 min-
1
0.080 min-1 0.062 min-
1
Table 6. Pharma algorithm results for Elvitegravir
ADME BOX Elvitegravir EL27 EL47 EL28 EL7
Oral bioavailability
between 30% and 70%
%F(Oral) > 30%: 0.888 0.827 0.888 0.541 0.541
%F(Oral) >70%: 0.480 0.388 0.820 0.121 0.110
Absorption
Maximum passive
absorption Contribution
from
Trancellular route 100% 100% 100% 100% 100%
Paracellular route 0% 0% 0% 0% 0%
Permeability:
Human Jejunum scale
(pH=6.5) Pe, Jejunum =
3.34x10-4
cm/s
3.38x10-4
cm/s
2.71x10
cm/s
2.71x10 1.06x10
Caco-2 scale (pH=7.4,
500 rpm): Pe, Caco-2
60.34x10-6
cm/s
62.71x10-
6 cm/s
32.21x10
cm/s
32.45x10 3.09x10
Absorption rate Ka =: 0.093 min-1 0.093
min-1
0.086
min-1
0.086 min-1 0.033 min-1
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The structures of the two drugs Raltegravir and Elvitegravir and the changes or modifications in
the two analogs (RL-10, EL -7) showing good protein binding are shown below.
Figure 5.  The structure of Raltegravir Figure 6. Structural analog of Raltegravir RL10
Figure 7.  The structure of Elvitegravir Figure 8. Structural analog of Elvitegravir EL7
Conclusion
From the molecular docking result carrying out using Molegro virtual docker, the best  four
analog form each inhibitor ( Raltegravir- RL-40,RL-13, RL -10, RL-9 ; Elvitegravir- EL-
27,EL-47,EL-28, EL-21 ) based on the mol dock score and the docking score were selected.
The close contacts shows that there is a high possibility of interaction of these analogs with the
amino acids of the active site of the  protein .These analogs also show better bioavailability
(RL 40 ; EL47) , protein binding  (RL 10, EL 7) ,solubility  (EL7, RL 10 ) and low toxicity
than existing two inhibitors  ( Raltegravir , Elvitegravir). These inhibitor analogs will provide a
platform for structure-based design of an additional class of inhibitors for antiviral therapy.
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